MicNova -Dec 21, 2017 Small Cap Stock Study: Cambrex (CBM)

Slides:



Advertisements
Similar presentations
NAIC Stock to Study for April 2005 Teva Pharmaceutical Industries Ltd Presented by: Ty Hughes NAIC DC Chapter April 12, 2005.
Advertisements

Analyzing Financial Statements
MGT 497 Financial, Trends, Ratios
UNLOCKING THE MAGIC OF NUMBERS UNLOCKING THE MAGIC OF NUMBERS 2 = DR. GEORGE WEBSTER EXECUTIVE EDUCATION PHARMACEUTICAL MARKETING.
1 FINANCIAL ANALYSIS 1. Financial Statement Analysis 2. Common Size Statement Analysis 3. Ratio Analysis 4. Sources/ Uses of Funds 5. Statement of Cash.
Financial Statement Analysis
Financial Statements Economics 98 / 198 Fall 2007 Copyright 2007 Jason Lee.
Valuation: Principles and Practice: Part 1 – Relative Valuation 03/03/08 Ch. 12.
 Broad-based health care company that discovers, develops, manufactures, and markets products and services  Abbott's main businesses: ◦ Global pharmaceuticals.
Financial Statement Analysis
CHAPTER 9 The Cost of Capital
Financial Statement Analysis
Key Financial Metrics Revisited: Calculations and Applications Rod Feuer & Prof. Frank Howland July 13, 2004.
Copyright © 2012 Pearson Education, Inc. Publishing as Prentice Hall. To make informed decisions about a company Helpful in managing the company Comparison.
FINANCIAL STATEMENT ANALYSIS UNIT 12 Analysing financial statements involves evaluating three characteristics of a company: 1. its liquidity 2. its profitability.
BIO-REFERENCE LAB BRLI Andrew Tiffany. Company Overview 3 rd largest full service lab in the U.S. Largest independent regional lab in the northeastern.
Created By: Garrett Kuhlmann, Ashton Wu Presented By: Japinder Nijjer – Head Analyst.
Financial Statement Analysis
Institut for Regnskab, Tom Hansen Corporate Valuation Current market value (slide 3, 1) Evaluating performance in the stock market. Cash flow of.
- Brijesh Pitroda. The analysis of a Business' Health starts with Financial Statement Analysis.
Analyst: Jeremy Leach and JohnPaul Bennett Thursday, November 5 th, 2009.
VULCAN MATERIALS CO. (VMC) Brenton Wanner. Overview  Largest producer  Cement  Concrete  Asphalt  10 States account for 85%  Acquired Florida Rock.
Assets Valuation Methods
Historical Performance Analysis Analysts:. 3-Year Compound Average Growth Rates.
Demonstration Problem
McGraw-Hill/Irwin Slide 1 Preliminary Press Releases Releasing Financial Information Quarterly and Annual Reports Securities and Exchange Commission (SEC)
Copyright © 2011 Pearson Education, Inc. Managing Your Money.
1 Prospects for the New Look Tenon John Dell Chief Executive, Tenon Limited Crowne Plaza Hotel, Auckland 16 November 2004.
Chapter 10 Questions and Answers Q1. Pennsylvania Clean Coal Company (“PCCC”) generates electricity for both industrial customers as well as consumer households.
[BUY/SELL]: [Company Name] Ticker: [Ticker] Date: [Today’s Date] Name: [Name of Group Members] [Company Logo Here]
Analysis of Financial Statements. Learning Objectives  Understand the purpose of financial statement analysis.  Perform a vertical analysis of a company’s.
TOPIC: COST OF FINANCIAL CAPITAL BASICS I. DETERMINANTS OF MARKET INTEREST RATES (k) [Also referred to as Quoted or Nominal interest rates] RW Melicher.
Analyzing Financial Statements Chapter 14 McGraw-Hill/Irwin © 2009 The McGraw-Hill Companies, Inc.
Corporate value model Also called the free cash flow method. Suggests the value of the entire firm equals the present value of the firm’s free cash flows.
McGraw-Hill/Irwin Copyright © 2005 by The McGraw-Hill Companies, Inc. All rights reserved. Chapter 19 Financial Statement Analysis.
Tellabs, Inc 4/1/02 Al Goldstein Economic Overview Economic Recovery is expected in 2002 –Strength of recovery is uncertain –Stock markets have surged.
Chipotle Mexican Grill (CMG) Stock Analysis April 14, 2010 Presented by: Mark Robertson.
1 Industry Study Education Segment Cincinnati Investment Model Club.
Financial Health of Li-ion Companies Jordan Baird HC 399.
Financial Projections as part of Business Plan by Ketoki Basu,
Why Cost of Capital? – Overall Cost of Capital of the Firm – Investment Proposal- Accept /Reject – Capital Structure – Yardstick to measure the worth of.
Copyright © 2007 Prentice-Hall. All rights reserved 1 Financial Statement Analysis Chapter 13.
Financials.
A beginner’s guide.  Prev Close:  Open: 106  1y Target Est:  Day’s Range:  52wk Range:
Tyler Hand , Enrique Cruz, Skye Galley
Historical Performance Analysis
Demonstration Problem
Mutual Funds and Other Investment Companies
Financial Statement Analysis
Financial Statement Analysis
Fundamental Valuation
Financial Statement Analysis
University of Winnipeg Investment Group
CCI Entrepreneurship Curriculum
Finance Review Byers.
Student Investment Management – Sector Presentation: Real Estate
Personal Finance Stocks (Equities)
Analysis of Financial Statements
CHAPTER 8 Stocks and Their Valuation
Fundamental Valuation
ANALYSIS OF FINANCIAL STATEMENTS
BK Sell pitch Financials IG.
Bank on the cheap or near cheap side.
Financial Industry Group 4/20/2011
Utilities Stock Presentation
Mr. Stasa- Willoughby-Eastlake City Schools
Adapted from Kathleen G Richards, “Quality Matters,” BINC 2019
ATD-B-TO Presentation 8/14/19 Sandy Caster - Part 4 of 4
MicNova’s Education Approach to Evaluating Stocks,
Presentation transcript:

MicNova -Dec 21, 2017 Small Cap Stock Study: Cambrex (CBM) Adapted from Manifest Investing’s Turnout Tuesday, Nov 6, 2017, by Mark Robertson https://www.manifestinvesting.com/

CAMBREX Corp. (CBM) Discussion by Mark Robertson and Ken Kavula

Manifest Investing’s Best Small Companies for 2018

Cambrex, analysis from Small Cap Informer, Nov 2017 Company Overview. One of the largest, & premium, manufacturers of small molecule and generic active pharmaceutical ingredients (APIs) compounds, used by other pharmaceutical companies. Sells its often niche- market compounds to leading pharmaceutical companies worldwide from six operating sites within the U.S., E.U., and India. Market Drivers. Continued world-wide growth for products; limited API manufacturing capacity, especially in U.S.; and customer preference for high-quality suppliers like Cambrex. Strong Pipeline. Early & late stage clinical projects and growing pipeline of new generic APIs in development. Examples of Products. Involved with Gilead’s 2014 & 2016 launch of HCV treatments; Courting other pharmaceutical companies; Treatments for pain & ADHD. Quality & Value Analysis. Quality: pre-tax profit margin and return on equity trending up; debt-free, cash available for acquisitions. Value: Projected high price in 5 years of $123 based on P/E of 19.

Review: Market Capitalization (from Investopedia) Mega-Cap: Over $200 B Big/Large Cap: $10B-$200B Medium Cap: $2B -$10B Small Cap: $300M -$2B Cambrex Corp, in 2017, has about 33.38M shares outstanding; price ~ $50/share, so Market capitalization is 33.38*$50 = $1.66 B First listed on NYSE – 1990 Ownership = about 83% institutions and mutual funds Micro-Cap: $50M -$300M

CBM Financial History ($M) , MorningStar

Value Line Analysis of Cambrex, Dec 2017

Analyses Variations for Projected Cambrex Performance Mark Robertson & Ken Kavula, November 8, 2017, Turnout Tuesday & Best Small Companies for 2018: Projected Sales Growth =11.4%; Proj Ann Ret = 15.6% Manifest Investing, December 2017, Equity Analysis Guide Projections: Sales Growth = 9.8%; Ann Ret = 9.5%; P/E =16; Price =$80 Value Line Dec 2017 Average annual return range, next 5 years: 5%-15%; Avg. P.E ration = 17.5; Price range/share = $60-$85 Gladys’s SSG for next 5 years: Estimated High and low P/Es = 14-19.5; Future Sales Growth & EPS = 7.1%; Annual return range =6.5%-10.2% Better Investing “Analysts” – 2 yr growth =5.2%, EPS = 10%

CAMBREX Corp. (CBM) Manifest Investing Projections – Dec 2017

Conclusion Cambrex is a Small Cap Stock that has grown and performed well in a niche health-care pharmaceutical market since 1990 It has a strong balance sheet and strong product pipeline Because it is a small company and dependent upon the sales of some of its large customers, like Gilead, the stock price and its performance can be volatile. Gladys’s SSG suggests the stock, at about $51/share, is in the “buy” range. Best return is more than 10%.

Addendum: Mark’s Best Sources for Small Company Ideas: Well-Run Mutual Funds